Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | HTR2C | P28335 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomilnacipran SCHEMBL12027608 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL114034 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL30083111 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL5504533 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL8099 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1707471 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Levomilnacipran SCHEMBL1414867 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL16241424 | 0.86 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| 1R,2S-Milnacipran SCHEMBL6061484 | 0.86 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| Milnacipran SCHEMBL1156056 | 0.86 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43879-E1 | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug | PIERRE FABRE MEDICAMENT (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-1485078-B1 | Milnacipran for the treatment of irritable bowel syndrome | CYPRESS BIOSCIENCE INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1578719-A4 | STEREOISOMERS OF P-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | COLLEGIUM PHARMACEUTICAL INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-7038085-B2 | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1578719-A2 | STEREOISOMERS OF P-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | Collegium Pharmaceutical, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040142904-A1 | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof | COLLEGIUM PHARMACEUTICAL INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004039320-A2 | STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142904-A1 | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof | SLC6A2, SLC6A4, OPRL1 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.